177Lu-PSMA Radioligand Therapy Is Favorable as Third-Line Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

Authors: Finn E. von Eyben, Kalevi Kairemo, Channing Paller, Manuela Andrea Hoffmann, Giovanni Paganelli, Irene Virgolini, Giandomenico Roviello

Source: Biomedicines, Vol 9, Iss 8, p 1042 (2021)

Subject Terms: advanced metastatic castration-resistant prostate cancer, connected network, frequentist analysis, benefits and harms of treatments, ranking of treatments, Biology (General), QH301-705.5

File Description: electronic resource

Relation: https://www.mdpi.com/2227-9059/9/8/1042; https://doaj.org/toc/2227-9059

Access URL: https://doaj.org/article/0db9479ec62d4c08a5ac981353300f63